Bariatric Times

NOV 2017

A peer-reviewed, evidence-based journal that promotes clinical development and metabolic insights in total bariatric patient care for the healthcare professional

Issue link: http://bariatrictimes.epubxp.com/i/893110

Contents of this Issue

Navigation

Page 19 of 32

19 Review Bariatric Times • November 2017 bowel bypass. Mayo Clin Proc. 1984;59:43–46. 17. Jorizzo JL, Schmalstieg FC, Dinehart SM, et al. Bowel- associated dermatosis-arthritis syndrome. Immune complex- mediated vessel damage and increased neutrophil migration. Arch Intern Med. 1984;144;738–740. 18. Decker GA, Swain JM, Crowell MD, Scolapio JS. Gastrointestinal and nutritional complications after bariatric surgery. Am J Gastroenterol. 2007;102: 2571–2580;quiz 2581. 19. Chan WW, Thompson CC, Lautz DB, Burakoff R. Risk of small intestinal bacterial overgrowth in Roux-en-Y gastric bypass. Gastroenterol. 2011;140;S-1057. 20. Lakhani SV, Shah HN, Alexander K, et al. Small intestinal bacterial overgrowth and thiamine deficiency after Roux-en-Y gastric bypass surgery in obese patients. Nutr Res. 2008;28:293–298. 21. Machado JD, Campos CS, Lopes Dah Silva C, et al. Intestinal bacterial overgrowth after Roux- en-Y gastric bypass. Obes Surg. 2008;18:139–143. 22. Nautiyal A, Singh S, Alaimo DJ. Wernicke encephalopathy—an emerging trend after bariatric surgery. Am J Med. 2004;117:804–805. 23. Salas-Salvado J, Garcia-Lorda P, Cuatrecasas G, et al. Wernicke's syndrome after bariatric surgery. Clin Nutr. 2000;19:371–373. 24. Lauritano EC, Gabrielli M, Scarpellini E, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci. 2009;13:111–116. 25. Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci. 2014;59:1278–1285. 26. Attar A, Flourie B, Rambaud JC, et al. Antibiotic efficacy in small intestinal bacterial overgrowth- related chronic diarrhea: a crossover, randomized trial. Gastroenterology. 1999;117:794–797. 27. Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007;25:781–786. 28. Singh VV, Toskes PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Gastroenterol Rep. 2003;5:365–372. 29. Sabate JM, Coupaye M, Ledoux, et al. Consequences of small intestinal bacterial overgrowth in obese patients before and after bariatric surgery. Obes Surg. 2017;27:599–605. 30. Andalib I, Shah H, Bal BS, et al. Breath hydrogen as a biomarker for glucose malabsorption after Roux- en-Y gastric bypass surgery. Dis Markers. 2015;2015:7. 31. Kong LC, Tap J, Aron-Wisnewsky J, et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr. 2013; 98:16–24. 32. Woodard GA, Encarnacion B, Downey JR, et al. Probiotics improve outcomes after Roux-en-Y gastric bypass surgery: a prospective randomized trial. J Gastrointest Surg. 2009;13:1198–1204. F UNDING: No funding was provided for this article. DISCLOSURES: The author reports no conflicts of interest relevant to the content of this article. ACKNOWLEDGEMENTS: The author thanks Barbra Blair of the Department of Infectious Diseases at Beth Israel Deaconess Medical Center for helpful comments and discussion. AUTHOR AFFILIATION: Diana Miao is with the Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA 02215 and Harvard Medical School, 25 Shattuck St., Boston, MA 02115. ADDRESS FOR CORRESPONDENCE: Diana Miao, AB; 260 Longwood Ave., TMEC 213, Boston, MA 02215. E-mail: diana_miao@hms.harvard.edu

Articles in this issue

Links on this page

Archives of this issue

view archives of Bariatric Times - NOV 2017